SAR405: Selective ATP-Competitive Vps34 Inhibitor for Autophagy and Vesicle Trafficking Modulation

Executive Summary: SAR405 is a potent, selective inhibitor of class III phosphoinositide 3-kinase (Vps34), showing a dissociation constant (Kd) of 1.5 nM and an IC50 of 1 nM for the human recombinant enzyme. It disrupts ATP binding, leading to impaired autophagosome formation and vesicle trafficking in mammalian cells (Park et al., 2023). SAR405 exhibits no measurable inhibition of class I/II PI3Ks or mTOR at concentrations up to 10 μM. Its effects are characterized by accumulation of swollen late endosome-lysosomes and defective cathepsin D maturation. SAR405 synergizes with mTOR inhibitors and serves as a validated, reproducible research tool for autophagy and disease modeling (APExBIO).

Biological Rationale

Autophagy is a conserved cellular pathway for the degradation and recycling of cytoplasmic components, essential for maintaining homeostasis during energy or nutrient stress (Park et al., 2023). Vps34, a class III PI3K, is critical for the nucleation of autophagic vesicles and the regulation of endosome-lysosome trafficking. Selective pharmacological inhibition of Vps34 enables precise dissection of autophagy initiation and vesicle maturation mechanisms. Tools like SAR405 are vital for elucidating the roles of PI3K signaling in cancer cell survival, neurodegeneration, and response to metabolic stress (see contrast with prior overview). Recent research suggests that the interplay between AMPK, ULK1, and Vps34 is more nuanced than previously assumed, with AMPK acting as a context-dependent regulator of autophagy (Park et al., 2023).

Mechanism of Action of SAR405

SAR405 is a small-molecule inhibitor designed to occupy the ATP binding cleft of human Vps34. By preventing ATP access, SAR405 abrogates the kinase activity required for phosphatidylinositol 3-phosphate (PI3P) production. This leads to inhibition of autophagosome formation and disruption of vesicle trafficking events downstream of Vps34. SAR405 does not inhibit class I or II PI3Ks, nor does it affect mTOR activity at concentrations up to 10 μM, demonstrating exquisite selectivity (APExBIO).

Cellular consequences of SAR405-mediated Vps34 inhibition include:

• Suppression of autophagosome biogenesis, as seen by the lack of GFP-LC3 puncta in HeLa and H1299 cells.
• Accumulation of swollen late endosome-lysosomes.
• Defective maturation of cathepsin D, indicating impaired lysosomal proteolysis.
• Synergistic autophagy blockade when combined with mTOR inhibitors such as everolimus.

Evidence & Benchmarks

• SAR405 exhibits a Kd of 1.5 nM for human recombinant Vps34 and an IC50 of 1 nM; no inhibition of class I/II PI3Ks or mTOR up to 10 μM (APExBIO).
• SAR405 blocks autophagosome formation in GFP-LC3 HeLa and H1299 cells under starvation conditions (Park et al., 2023).
• Combining SAR405 with mTOR inhibitors (e.g., everolimus) leads to synergistic inhibition of autophagy, exceeding effects of either agent alone (Park et al., 2023).
• Vps34 inhibition by SAR405 results in defective cathepsin D maturation and accumulation of swollen endosomes in mammalian cells (see expanded mechanistic review).
• SAR405 is soluble in DMSO (>10 mM) and ethanol (with ultrasound), but insoluble in water (APExBIO).
• Autophagy induction by AMPK is context-dependent; energy crisis conditions can override canonical ULK1 activation (Park et al., 2023).

Applications, Limits & Misconceptions

SAR405 is routinely used in cellular assays to study autophagy, vesicle trafficking, and related signaling pathways in cancer and neurodegenerative disease models. Its selectivity profile enables researchers to distinguish Vps34-dependent events from other PI3K/mTOR-mediated processes (contrasted to workflow Q&A). In translational research, SAR405 is used to dissect autophagosome formation blockade and to characterize the consequences of vesicle trafficking modulation.

Common Pitfalls or Misconceptions

• SAR405 does not inhibit class I/II PI3Ks or mTOR: It should not be used to study these isoforms (APExBIO).
• Not a direct AMPK inhibitor: SAR405 acts downstream of ULK1 and is not suitable for probing AMPK-driven autophagy regulation (Park et al., 2023).
• Not water-soluble: SAR405 requires DMSO or ethanol (with ultrasound) for dissolution; improper solubilization can affect bioavailability (APExBIO).
• Does not induce autophagy: SAR405 is a selective inhibitor and blocks autophagosome biogenesis, rather than promoting it.
• Long-term solution storage is not recommended: Prepare fresh stock below -20°C for optimal potency (APExBIO).

Workflow Integration & Parameters

For experimental use, SAR405 (SKU A8883, APExBIO) is supplied as a solid. Dissolve in DMSO at >10 mM for stock solutions. For cell-based assays, a final concentration of 1–10 nM is typical, with exposure durations of 2–24 hours depending on the endpoint. For ethanol dissolution, sonicate to enhance solubility. Store aliquots below -20°C and avoid repeated freeze-thaw cycles. For autophagy inhibition, monitor the absence of GFP-LC3 puncta or LC3-II conversion. In vesicle trafficking assays, assess endosome-lysosome morphology and cathepsin D maturation. SAR405 is compatible with mTOR inhibitors for combinatorial studies, providing robust autophagosome formation blockade (expanding on strategic integration).

Conclusion & Outlook

SAR405 is a validated, highly selective ATP-competitive Vps34 inhibitor for dissecting autophagy mechanisms and vesicle trafficking in mammalian systems. Its nanomolar potency and clear selectivity profile position it as a gold-standard pharmacological tool in cancer, neurodegenerative disease, and basic cell biology research. The compound’s compatibility with mTOR inhibitors and its ability to clarify autophagy regulation under energetic stress make it especially valuable in light of new findings on ULK1 and AMPK signaling (Park et al., 2023). By leveraging SAR405, researchers can rigorously interrogate Vps34 kinase signaling, enabling reproducible, interpretable data and supporting advances in targeted therapy and disease modeling.